WAVE Life Sciences – IPO

Boston – December 7, 2015 – Cooley advised the underwriters on WAVE Life Sciences' $102 million initial public offering. WAVE Life Sciences is a preclinical biopharmaceutical company with an innovative and proprietary synthetic chemistry drug development platform that it is using to design, develop and commercialize a broad pipeline of first-in-class or best-in-class nucleic acid therapeutic candidates. The company now trades on the NASDAQ Global Market under the symbol "WVE."

Jefferies and Leerink Partners acted as joint book-running managers for the offering. JMP Securities and SunTrust Robinson Humphrey acted as co-managers for the offering.

The Cooley corporate and securities team advising the underwriters included Frank Rahmani, Nicole Brookshire, John McKenna, Alison Haggerty, David Bartholomew, Maggie Siegel and Layne Jacobs.

Critical support for the offering was provided by Natasha Leskovsek, Phil Mitchell and Leah Roffman (health care and life sciences regulatory); Ivor Elrifi, Heidi Erlacher and Lian Ouyang (IP); Joshua Friedman and Jessica Mols (compensation and benefits); and Jeremy Naylor and Todd Gluth (tax).

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 850 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
John McKenna Partner, Palo Alto
Nicole Brookshire Partner, Boston
Natasha Leskovsek Of Counsel, Washington, DC
Phil Mitchell Partner, New York
Ivor Elrifi Partner, New York
Heidi A. Erlacher Partner in Charge – Boston
Todd Gluth Partner, San Diego
Layne Jacobs Associate, Boston
Joshua Friedman Partner, Boston